Global Ganja Report

A bill that would legalize "recreational" cannabis is moving forward in Hawaii's state legislature. It would build on the dispensary system established by the state's medical marijuana program to bring about a regulated adult-use market.

CBD-infused foods and beverages are the target of a crackdown in New York City, as well as Maine and Ohio. A budding business of cannabinoid-enhanced concoctions and libations is feeling a sudden pinch. But some media coverage is failing to make clear that what is at issue here is the FDA's failure to keep pace with federal law—not any inherent risks of cannabidiol.

Already officially studying the possibility of cannabis legalization, Mexico's new President López Obrador has now announced a formal end to the "war on drugs" that has only seemed to fuel the narco-violence over the past 10 years.  However, military troops are still being mobilized for narcotics enforcement—including marijuana eradication.

The World Health Organization has released its long-anticipated recommendation on cannabis scheduling. But rather than removing it from Schedule I of the Single Convention, it only removes it from Schedule IV, where it is also listed. CBD, however, has indeed been de-scheduled entirely.

In Arizona, the statehouse and supreme court are in a race to clarify whether hashish is to be included in the Grand Canyon State's medical marijuana program. The question also has implications for the status of extracts and edibles.

A Chinese delegation to Israel to explore cooperation in the cannabis sector points to the East Asian giant's growing footprint in the global industry. But in a continued contradiction, the People's Republic has possibly the harshest drug laws on Earth—and, where unsanctioned use by the commoners is concerned, cannabis is no exception.

In Episode 24 of the CounterVortex podcast, Bill Weinberg notes the historic strides toward liberation of the cannabis plant in 2018, from the fabled four corners of the Earth. Yet under capitalism, every advance also opens new contradictions.

With passage of the Farm Bill and removal of hemp-derived CBD from controlled substance status, big market growth is expected for the very chic and purportedly salubrious non-psychoactive cannabinoid. The law is a win for a nascent CBD industry that has been struggling to shake off the lingering stigma surrounding (psychoactive) cannabis. The effort to segment cannabidiol from "marijuana" is exemplified in the several states that now have "CBD-only" laws.